- In December 2024, Merck announced the top line results from its pivotal Phase 3 trials evaluating the investigational once-daily oral two-drug single-tablet regimen of doravirine/islatravir (DOR/ISL) for treating HIV in adults. The trial demonstrated the regimen’s effectiveness and safety, aiming to provide a more convenient and effective treatment option. This new treatment could benefit patients by offering a simpler, daily oral regimen with potentially fewer side effects compared to current treatments. It also supports Merck's position in the HIV treatment market by enhancing patient adherence and expanding treatment options.
- In October 2024, Illumina launched its new MiSeq Series with XLEAP Chemistry RT reagents**, designed to enhance next-generation sequencing (NGS) capabilities. This advancement will significantly improve the accuracy and efficiency of genomic analysis, particularly in the detection of viruses and contaminants in biologic products. The new system aims to provide faster, more reliable sequencing results, which are essential for viral clearance testing in drug development. The benefits include higher throughput, reduced costs, and increased precision, ultimately supporting biopharmaceutical companies in ensuring the safety and quality of biologics and advancing therapeutic innovations.
